share_log

Biomea Fusion Shares Are Trading Lower. The Company Reported Phase II Results for Icovamenib in Type 2 Diabetes.

Benzinga ·  Dec 17, 2024 21:49
Biomea Fusion Shares Are Trading Lower. The Company Reported Phase II Results for Icovamenib in Type 2 Diabetes.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment